Table 2.
Precision and recall (P&R) of TSS and PubMed (PM). Qualitative significance and relevance criteria were applied in determining P&R.
| Search term | TSS | PM | Precision (TSS) | Recall (TSS) | Precision (PM) | Recall (PM) |
|---|---|---|---|---|---|---|
| Condition and intervention | ||||||
| Systemic sclerosis AND Rituximab | 5 | 14 | 1.00 | 0.50 | 0.71 | 1 |
| Asthma AND Matrix Metalloproteinase 12 | 1 | 3 | 1.00 | 1.00 | 0.33 | 1 |
| Varicella AND Acyclovir | 2 | 48 | 1.00 | 0.33 | 0.13 | 1 |
| Sickle cell disease AND Nitric oxide | 7 | 31 | 1.00 | 0.54 | 0.42 | 1 |
| Brain trauma AND Serum S‐100 | 4 | 18 | 1.00 | 0.50 | 0.44 | 1 |
| Condition | ||||||
| Ochronosis | 2 | 17 | 1.00 | 0.50 | 0.24 | 1 |
| Medullary carcinoma thyroid | 41 | 182 | 1.00 | 0.43 | 0.66 | 1 |
| Schistosomiasis | 115 | 520 | 0.99 | 0.29 | 0.90 | 1 |
| Dupuytren’s contracture | 5 | 39 | 1.00 | 0.19 | 0.67 | 1 |
| Pseudoxanthoma Elasticum | 10 | 46 | 0.90 | 0.25 | 0.78 | 1 |
| Intervention | ||||||
| Rivaroxaban | 33 | 72 | 1.00 | 0.77 | 0.60 | 1 |
| Fenofibrate | 35 | 186 | 0.94 | 0.18 | 0.96 | 1 |
| Mineralocorticoid receptor | 57 | 274 | 1.00 | 0.21 | 0.99 | 1 |
| P2Y12 antagonists | 28 | 65 | 1.00 | 0.44 | 0.97 | 1 |
| Phosphodiesterase III | 19 | 93 | 1.00 | 0.25 | 0.84 | 1 |
| Totals (citations retrieved/citations reviewed) | 364/364 | 1,608/870 | ||||
| Average | 0.99 | 0.47 | 0.58 | 1.00 | ||